Molenzavir(Molnupiravir)

Therapeutic Group: Anti Viral

Presentation

Molenzavir 200 Capsule: Each capsule contains Molnupiravir INN 200 mg.

Description

Molnupiravir is an investigational antiviral drug, which is the prodrug of the ribonucleoside analog N4-hydroxycytidine. It inhibits the replication of multiple RNA viruses, including

SARS-CoV-2. It has broad spectrum antiviral activity against influenza virus and coronaviruses, such as MERS-CoV, and SARS-CoV. It is aimed at the treatment of COVID-19 in-

• patients hospitalized due to mild, moderate or severe disease,

• non-hospitalized patients with mild or moderate disease.

Indications

Molnupiravir is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.

Dosage & Administration

* 800 mg (4 capsules), Twice daily, 5 days, Orally
The safety & efficacy of Molnupiravir in patients below 18 years of age have not been established. No dosage adjustment is required for renal, hepatic impairment & elderly
patients.

Side Effects

Common adverse reactions are diarrhoea, nausea, dizziness, headache, rash and urticaria etc

Precautions

N/A

Use in Pregnancy & Lactation

There are no data from the use of Molnupiravir in pregnant women. Studies in animals have shown reproductive toxicity. It is not recommended during pregnancy.
It is unknown whether Molnupiravir or any of the components of Molnupiravir is present in human milk, affects human milk production, or has effect on the breastfed infant.

Drug Interaction

No drug interactions have been identified based on the limited available data. No clinical interaction studies have been performed with molnupiravir

Storage

Do not store above 30 ⁰C. Keep away from light and out of the reach of children.

Commercial Pack

Molenzavir 200: Each box contains 5 Alu-Alu blister strips of 4 capsules.